Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES)
November 21 2017 - 09:00AM
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage
specialty pharmaceutical company dedicated to developing and
commercializing innovative pharmaceutically-produced transdermal
cannabinoid treatments, today announced the acceptance and
presentation details of a Late Breaking poster at the 2017 Annual
Meeting of the American Epilepsy Society (AES) in Washington, DC,
taking place December 1 through December 5, 2017.
Sunday, December 3, 2017
Poster title: “Synthetic Transdermal Cannabidiol for the
Treatment of Focal Epilepsy in Adults”Poster session:
2 Poster number: 428Author
presentation time: 12:00PM – 2:00PM EST Display time:
10:00AM – 4:00PM EST Location: Hall B, Lower LevelAbstract
ID: 2.428
About Zynerba Pharmaceuticals,
Inc. Zynerba Pharmaceuticals (NASDAQ:ZYNE) is dedicated to
improving the lives of people with severe health conditions where
there is a high unmet medical need by developing and
commercializing pharmaceutically-produced transdermal cannabinoid
medicines designed to meet the rigorous efficacy and safety
standards established by global regulatory agencies. Through the
discovery and development of these life-changing medicines, Zynerba
seeks to improve the lives of patients battling severe, chronic
health conditions including epilepsy, Fragile X syndrome,
osteoarthritis, fibromyalgia and peripheral neuropathic pain. Learn
more at www.zynerba.com and follow the Company on Twitter at
@ZynerbaPharma.
Zynerba ContactWill Roberts, VP Investor
Relations and Corporate
Communications484.581.7489robertsw@zynerba.com
Media contactTheresa Dolge Tonic Life
CommunicationsOffice: 215-928-2748Theresa.Dolge@toniclc.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Feb 2024 to Mar 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Mar 2023 to Mar 2024